Soligenix CEO Christopher Schaber Buys 15,132 Shares at $1.32 Per Share

Soligenix, Inc. (SNGX) has recently announced that Christopher J. Schaber, the company's Director, Chairman, CEO, and President, has made a significant purchase of 15,132 shares at a price of $1.32 per share on October 2, 2025.

Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, has announced a significant share purchase by its Director, Chairman, CEO, and President, Christopher J. Schaber. On October 2, 2025, Schaber purchased 15,132 shares of the company's common stock at a price of $1.32 per share Soligenix Says On Sept 25, Entered Securities Purchase Agreement With Investors - SEC Filing^[1].

This purchase comes at a time when Soligenix is extending its cash runway through 2026, following the closing of a $7.5 million public offering on September 29, 2025. The company received gross proceeds of approximately $7.5 million from the sale of 5,555,560 shares of common stock, which will be used to fund research and development, commercialization activities, and general corporate purposes Soligenix Announces Closing of $7.5 Million Public Offering^[2].

The company's latest filings indicate that Schaber's purchase was made at a price slightly below the current market price, reflecting a potential long-term commitment to the company's future prospects. The purchase aligns with Schaber's previous investment in the company, demonstrating his confidence in Soligenix's pipeline of therapeutic products, including HyBryte™ (SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL) and other rare diseases.

Soligenix's recent financial activities underscore its strategic focus on securing funding to support its ambitious development programs. The company's Specialized BioTherapeutics business segment is developing several innovative therapies, while its Public Health Solutions business segment is focused on vaccine candidates for bioterror threats and COVID-19. The company's strong pipeline and commitment to addressing unmet medical needs position it as a key player in the biopharmaceutical industry.